Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence

Arrigo FG Cicero, Elisa Tartagni, Sibel Ertek
  • Expert Opinion on Biological Therapy, March 2014, Informa Healthcare
  • DOI: 10.1517/14712598.2014.902929

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1517/14712598.2014.902929

The following have contributed to this page: Dr Arrigo FG CICERO